Access to eClinical knowledge, best practices and financial benefits aims to maximize CROs’ business and scientific success

SNBL USA wins BARDA contract for chemical, radiological and nuclear animal model development

Results of Compugen collaboration with Iain B. McInnes of Glasgow University presented at rheumatology meeting

Nonprofit has been established in large part to strengthen protections for research participants

Full data set from ANNEXA-R also presented in late-breaking clinical trial session at AHA Scientific Sessions 2015

Human Longevity launches Health Nucleus to provide most complete picture ever of human health with genomics and more

The challenge of delivering on the promise of delivering genes as therapeutics

Eleven HIV patients successfully reach one year of full virologic suppression in PRO 140 monotherapy Phase 2b extension study

Acquisition expands company’s product pipeline, delivers greater manufacturing and supply chain control and is expected to be immediately accretive to revenue, earnings and operating cash flows

5th Annual Conference and Exhibition of the Society for Laboratory Automation and Screening (SLAS) to meet in San Diego and has added a new track focused on cellular technologies

Teva to receive worldwide development and commercial rights to novel CGRP antagonists; Heptares to receive $10 million upfront with up to $400 million in potential milestone payments

Kura Oncology, Inc., has announced that the first patient has been dosed in an investigator-sponsored Phase 2 trial of its lead drug candidate, tipifarnib, an inhibitor of protein farnesylation, in cancer patients with urothelial carcinoma tumors characterized by HRAS mutations.